Ulthera, Inc., an international medical device company that produces the ultrasound platform device Ulthera System, has received FDA clearance for this technology for the treatment of lines and wrinkles of the décolleté. This makes Ulthera System, the company’s signature aesthetics technology, to be the first non-surgical procedure specifically indicated by the FDA to aesthetically treat the chest and improve the signs of aging on the décolleté.
The Ultherapy® Decolletage Treatment makes use of Ulthera System’s proven and highly effective imaging and micro-focused ultrasound therapy capabilities. A single treatment session can be completed in about half an hour. The penetration of ultrasound energy into the deeper layers of the skin causes the natural stimulation and production of collagen and elastin. With new collagen and elastin appearing in the skin’s foundation, it gradually helps smooth the wrinkles and lines from the chest.
Natural Looking Results
The results are more naturally looking with this treatment because the process occurs internally and makes a gradual impact. It will usually take about three months for the full results to appear. The Ulthera System has already been FDA-cleared for lifting the neck, eyebrow and under the chin, with significant benefits achieved in just a single treatment. Similar outcomes are also achieved for the decolletage treatment. The procedure involves no downtime and there are no post-procedure care requirements.
Consistent, Safe, Painless
Many experienced dermatologists report that there is a high demand from patients to provide a safe and effective procedure to treat the aging signs on the chest. Patients are keen to choose solutions that do not involve invasive treatment. However, the proven and established treatments available to reduce lines and wrinkles from the chest typically involve needles, incisions, multiple treatments, prolonged recovery, and restrictions against sun exposure.
Now with the FDA clearance of the Ultherapy® Decolletage Treatment, dermatologists have a safe, effective, and comfortable solution that produces consistent results. The procedure can be performed during the lunch hour, so the working people do not even have to take time off from work. The treatment can be undertaken at any time of the year and without any downtime involved.
Expanding Scope of Treatment
The president and CEO of Ulthera, Inc., Matthew E. Likens, has said that receiving FDA clearance for Ulthera System to treat the décolleté indication fills a very clear void for patients. The company is committed to expanding the scope of its platform technology. The dermatology practices that support the state of the art Ulthera System can now address a wider range of aesthetic needs for their patients with this technology.
The company’s goal is to ensure that greater value is added to the Ulthera System each year for the providers for the Ulthera treatment. With the latest FDA clearance, the Ultherapy® treatment now addresses four key areas, ranging from the brow to the chest. The company is pleased that its efforts in research and development are producing real benefits for the patients. The Ultherapy® technology is already cleared in more than 40 countries around the world, and has displayed an excellent safety and performance record.